Rare Disease Trial, Recruiting (NCT06213402)

Rare Disease Trial, Recruiting NCT06213402 Sponsor: Hospital Universitari Vall d'Hebron Research Institute Condition: Rare Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06213402 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rare Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People of any age from 0 to 100 years old, both female and male
People who have been diagnosed with a rare anaemia disorder (RAD), including Sickle Cell Disease (SCD), Thalassaemia (THAL), Pyruvate Kinase Deficiency (PKD), or other similar rare inherited blood conditions classified under a recognised medical database called ORPHANET
People (or their legal guardian/parent if they are a minor) who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

People (or their legal guardian/parent if they are a minor) who are not willing or not able to give their written consent to take part
People who only carry a mild or "trait" version of Sickle Cell Disease or Thalassaemia (including alpha-thalassaemia and beta-thalassaemia traits), meaning they carry the gene but do not have the full condition — the same applies to trait versions of other similar inherited blood conditions (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: María del Mar Manú Pereira, PhD, Vall d'hebron Research Institute - Vall d'Hebron Research Institute - University Hospital Vall d'Hebrón (VHIR/HUVH)

Phone: 0034934893000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06213402

Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Phase: Not Applicable

Status: Recruiting

Condition: Rare Disease

Trial contact: 0034934893000

More information: https://clinicaltrials.gov/study/NCT06213402

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People of any age from 0 to 100 years old, both female and male
People who have been diagnosed with a rare anaemia disorder (RAD), including Sickle Cell Disease (SCD), Thalassaemia (THAL), Pyruvate Kinase Deficiency (PKD), or other similar rare inherited blood conditions classified under a recognised medical database called ORPHANET
People (or their legal guardian/parent if they are a minor) who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

People (or their legal guardian/parent if they are a minor) who are not willing or not able to give their written consent to take part
People who only carry a mild or "trait" version of Sickle Cell Disease or Thalassaemia (including alpha-thalassaemia and beta-thalassaemia traits), meaning they carry the gene but do not have the full condition — the same applies to trait versions of other similar inherited blood conditions (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Registry

ClinicalTrials.gov

Start date

30 November 2021

Est. completion

1 December 2024

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Estimation of Prevalence and Incidence of RADs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov